Evidence map›Paper›PMID 31073972›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.

A Fernandez Montes, F Vazquez Rivera, N Martinez Lago, M Covela Rúa, A Cousillas Castiñeiras, P Gonzalez Villarroel, J de la Cámara Gómez, J C Méndez Méndez, M Salgado Fernández, S Candamio Folgar and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

A Fernandez MontesMedical Oncology Department, Complexo Hospitalario Universitario de Ourense, C/Calle Ramon Puga Noguerol, 54, s/n, 32005, Ourense, Spain. afm1003@hotmail.com.ORCID http://orcid.org/0000-0003-4630-5830
F Vazquez RiveraMedical Oncology Department, Hospital Clínico Universitario de Santiago, Rúa da Choupana, s/n, 15706, Santiago, A Coruña, Spain.
N Martinez LagoMedical Oncology Department, Hospital Universitario A Coruña, C/As Xubias, s/n, 15006, A Coruña, Spain.
M Covela RúaMedical Oncology Department, Hospital Universitario Lucus Augusti, C/Dr. Ulises Romero, 1, 27003, Lugo, Spain.
A Cousillas CastiñeirasMedical Oncology Department, Hospital Provincial de Pontevedra, C/Loureiro Crespo, 2, 36002, Pontevedra, Spain.
P Gonzalez VillarroelMedical Oncology Department, Hospital Universitario Álvaro Cunqueiro, C/Estrada de Clara Campoamor, 341, 36312, Vigo, Pontevedra, Spain.
J de la Cámara GómezMedical Oncology Department, Hospital Universitario Arquitecto Marcide, Av. da Residencia, s/n, 15405, El Ferrol, A Coruña, Spain.
J C Méndez MéndezMedical Oncology Department, Centro Oncológico de Galicia, Rúa Doctor Camilo Veiras, 1, 15009, A Coruña, Spain.
M Salgado FernándezMedical Oncology Department, Complexo Hospitalario Universitario de Ourense, C/Ramón Puga, s/n, 32005, Ourense, Spain.
S Candamio FolgarMedical Oncology Department, Hospital Clínico Universitario de Santiago, Rúa da Choupana, s/n, 15706, Santiago, A Coruña, Spain.
M Reboredo LópezMedical Oncology Department, Hospital Universitario A Coruña, C/As Xubias, s/n, 15006, A Coruña, Spain.
M Carmona CamposMedical Oncology Department, Hospital Universitario Lucus Augusti, C/Dr. Ulises Romero, 1, 27003, Lugo, Spain.
E Gallardo MartínMedical Oncology Department, Hospital Provincial de Pontevedra,, C/Loureiro Crespo, 2, 36002, Pontevedra, Spain.
M Jorge FernándezMedical Oncology Department, Hospital Universitario Álvaro Cunqueiro, C/Estrada de Clara Campoamor, 341, 36312, Vigo, Pontevedra, Spain.
M L Pellón AugustoMedical Oncology Department, Hospital Universitario Arquitecto Marcide, Av. da Residencia, s/n, 15405, El Ferrol, A Coruña, Spain.
L París BouzasMedical Oncology Department, Centro Oncológico de Galicia, Rúa Doctor Camilo Veiras, 1, 15009, A Coruña, Spain.
J García GómezMedical Oncology Department, Complexo Hospitalario Universitario de Ourense,, C/Calle Ramon Puga Noguerol, s/n, 32005, Ourense, Spain.
Complexo Hospitalario Universitario A Coruña · ESUniversity Hospital Complex Of Vigo · ESCentro Oncológico de Galicia · ESComplejo Hospitalario de Pontevedra · ESComplejo Hospitalario Universitario de Ferrol · ESComplejo Hospitalario Universitario de Santiago · ESHospital Universitario Lucus Augusti · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTrifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. PATIENTS AND

methodsThis is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies.

resultsA total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml.

conclusionThe results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.

Indexed as

NomogramsAdultAgedAged, 80 and overColorectal NeoplasmsDrug CombinationsDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProgression-Free SurvivalPyrrolidinesResponse Evaluation Criteria in Solid TumorsDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilMetastatic colorectal cancerNomogramPrognostic factorsReal-lifeRefractoryTrifluridine/tipiracil

Identifiers

PMID31073972
OpenAlexW2944159393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.